Search

Moxetumomab pasudotox

This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion … CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt's lymphoma.

Sodium borate

Istradefylline

[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A_2A receptors in the basal ganglia. … [L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]

Milciclib Maleate

Milciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy).

Glycyrrhiza glabra

Glycyrrhiza glabra is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Udenafil

Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. … It is not yet approved for use in the U.S., E.U., or Canada.

Imelasomeran

[L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922] … Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.

Simvastatin

were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%. … [A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line

Pegcetacoplan

Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]

Edetate calcium disodium anhydrous

Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. … [L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]